Skip to main content

Tranzyme, Active Pass Enter Gene Expression Collaboration

NEW YORK, Sept. 20 – Tranzyme of Birmingham, Ala., and Active Pass Pharmaceuticals of Vancouver, said Thursday they had agreed to combine their technologies in an effort to study gene expression and bolster their drug discovery programs.

Under the terms of the deal, Active Pass will provide sets of gene sequences that make up the molecular pumps, or ABC transporters, located in the membranes of all cells, while Tranzyme will use its Tranz Expression Technology to deliver these genes into mammalian cells. By doing this, the companies said they would be able to gain a better of understanding of tene expression and the proteins involved in cells of interest.

"Combining Tranzyme's technology with our existing suite of ABC transporter gene sequences is a key step in advancing our chemogenomic strategy," Peter Reiner, CEO of Active Pass Pharmaceuticals, said in a statement.

Financial terms of the deal were not disclosed.

Tranzyme said its deal with Active Pass was its second since introducing the Tranz Expression Technology in August. Last month, the company announced a collaboration with NeoGenesis Drug Discovery of Cambridge, Mass. Tranzyme said it is in talks with at least 12 potential partners.

Tranzyme is a privately held biotechnology company that develops technologies for applied genomics, proteomics, and drug discovery.

Active Pass Pharmaceuticals is also privately held. Its main objective is to develop drugs that target ABC transporters.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.